Search

Meet Willem Fibbe, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.

Read more

Meet Achille Iolascon, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I serve the EHA as chairman of the Study working group on “Red cells and iron” since June 2014.

Read more

Meet Achille Iolascon, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I serve the EHA as chairman of the Study working group on “Red cells and iron” since June 2014.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

Join EHA and BSH and receive a discount on your EHA membership fee!

We are pleased to inform that EHA and the British Society of Haematology (BSH) have joined forces and are offering you the possibility of an EHA-BSH Joint Membership.

Read more

Clinical Research Training in Hematology

The CRTH 2025 call for applications is open until August 30, 2024 (12:00 CEST).

Read more

Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia

At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.

Read more

Travel Grants

Application for a travel grant closed on August 29

Travel grants are intended to support young investigators; therefore, applicants should be 36 years of age or young and are reserved for applicants from upper-middle, lower-middle, and low-income countries.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more